Miach Orthopaedics’ BEAR® Implant Granted FDA De Novo Approval for Treatment of ACL Tears

Implant Is First New Treatment for ACL Tears in 30+ Years; Enables Injured ACL to Heal Itself

WESTBOROUGH, Mass.–(BUSINESS WIRE)–#ACLreconstruction—Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, today announced that the U.S. Food & Drug Administration has granted the company’s De Novo Request for the Bridge-Enhanced® ACL Repair (BEAR®) Implant, resulting in marketing approval for the treatment of anterior cruciate ligament (ACL) tears, one of the most common knee injuries in the U.S. The BEAR Implant is the first medical technology to clinically demonstrate that it enables healing – or restoration – of the patient’s torn ACL. This new approach is a paradigm shift from the current standard of care – reconstruction that replaces the ACL with a graft – and is the first new treatment for ACL tears in more than 30 years.

“ACL injuries are all too common among athletes of all ages and can be a career-ending injury in the NFL, which is why the NFL Players Association has been a sponsor of the BEAR clinical trials since the beginning,” said Sean Sansiveri, vice president, National Football League Players Association. “We’re gratified to have supported Miach Orthopaedics in the journey to bring a better option for treating ACL injuries to patients in the U.S.”

Every year, approximately 400,000 ACL injuries occur in the U.S. A torn ACL does not heal on its own, resulting in ACL reconstruction being one of the most common orthopedic procedures in the U.S. Yet the procedure has many drawbacks; many people are unable to return to the same level of daily activities or sports.

“There are a number of advantages to repairing a ligament instead of replacing it. That is why, more than 30 years ago, we set out to find a way to help the ligament heal itself,” said Martha Murray, M.D., founder of Miach Orthopaedics and professor of orthopaedic surgery at Boston Children’s Hospital/Harvard Medical School. “We’ve been encouraged by the results of the clinical studies at Boston Children’s Hospital showing that repair using a BEAR Implant is a viable alternative to autograft ACL reconstruction. FDA approval validates the decades of work our teams have put into this technology and is truly rewarding. We are looking forward to seeing this technology become more widely available for patients everywhere.”

The proprietary, bio-engineered BEAR Implant facilitates healing of the torn ACL and has several benefits over ACL reconstruction: It restores natural anatomy and function of the knee, is less invasive and has better patient satisfaction in terms of readiness to return to sport and one-year pain and symptoms. The BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or using a deceased donor’s tendon that requires special storage and handling requirements.

“Preserving a patient’s native ACL instead of replacing it with a graft has long been a goal of surgeons, and before the BEAR Implant, multiple approaches were studied and failed,” said Martha Shadan, president and CEO, Miach Orthopaedics. “The BEAR Implant, which is the first medical technology to show that it enables a patient’s own torn ACL to heal, represents the first substantial advancement in the treatment of ACL tears in decades and has the potential to change the standard of care.”

The FDA submission for the BEAR Implant was based on the results of the BEAR II clinical trial. Two-year follow-up data showed the BEAR Implant was non-inferior to autograft ACL reconstruction in patients ages 14-35. Compared with autograft ACL reconstruction, the BEAR Implant also showed faster recovery of muscle strength and higher patient satisfaction with regard to readiness to return to sports and Knee Injury and Osteoarthritis Outcome Score (KOOS) measures of pain and symptoms. Magnetic resonance imaging (MRI) indicated that the BEAR Implant facilitates healing of the native ACL so that, at two years, its size, geometry and tissue composition are more similar to native ACL tissue than autograft. Pre-clinical studies suggest that the BEAR Implant may reduce the rate of osteoarthritis, estimated to occur in 78% of people with ACL tears, but this has not yet been confirmed in human trials.¹

Miach Orthopaedics plans to conduct a limited market release of the BEAR Implant in early 2021.

About The BEAR® Implant

Miach Orthopaedics’ new Bridge-Enhanced® ACL Repair (BEAR®) Implant is a proprietary bio-engineered implant used to facilitate healing of the torn ACL. Unlike reconstruction, which is the current standard of care, the BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or using a deceased donor’s tendon. The BEAR Implant acts as a bridge between the two ends of the torn ACL. The surgeon injects a small amount of the patient’s own blood into the implant and inserts it between the torn ends of the ACL in a minimally invasive procedure. The combination of the BEAR Implant and the patient’s blood enables the body to heal the torn ends of the ACL back together while maintaining the ACL’s original attachments to the femur and tibia. As the ACL heals, the BEAR Implant is absorbed by the body, within approximately eight weeks.

The BEAR Implant is indicated for skeletally mature patients at least 14 years of age with a complete rupture of the ACL, as confirmed by MRI. Patients must have an ACL stump attached to the tibia to construct the repair. The BEAR device must be implanted within 50 days of injury.

About Miach Orthopaedics, Inc.

Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to developing bio-engineered surgical implants for connective tissue repair. The company’s initial focus is the Bridge-Enhanced® ACL Repair (BEAR®) Implant, which represents a paradigm shift in the treatment of ACL tears from reconstruction to restoration. The BEAR technology was pioneered by Martha Murray, M.D., founder of Miach Orthopaedics, at the Boston Children’s Hospital Department of Orthopaedic Surgery, with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Facebook, Twitter and LinkedIn.

¹ Murray MM, Fleming BC. Use of a bioactive scaffold to stimulate anterior cruciate ligament healing also minimizes posttraumatic osteoarthritis after surgery. Am J Sports Med. 2013;41(8):1762-1770.

Contacts

Joni Ramirez

Merryman Communications

joni@merrymancommunications.com
323-532-0746